Clicky

Anavex Life Sciences Corp.(AVXL) News

Date Title
Jan 24 Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why
Jan 21 Best Momentum Stocks to Buy for January 21st
Dec 31 Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?
Dec 30 All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy
Sep 3 Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
Jul 30 Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
Jul 29 Neurodegenerative Disease-Focused Anavex Life Sciences' Alzheimer's Candidate Slows Disease Progression By Almost 39%
Jul 29 Anavex seek EMA approval despite shaky pivotal Alzheimer’s trial data
Jul 28 Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
Jun 20 Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
May 15 Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
May 14 Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
May 10 Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript
May 9 Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
May 2 Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
Apr 11 Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
Mar 25 Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Mar 18 Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Jan 16 Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Jan 9 Anavex (AVXL): Strong Industry, Solid Earnings Estimate Revisions